141080 · KOSDAQ · ₩141080 · 리가켐바이오
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−71.6% from the high
₩61,600Today: ₩63,200 – ₩67,300₩225,000
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 27: buy ₩812M at the close (5.1% of 20-day average trading value)
On its 24 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 13.7% of trading value and pointed the same way 22 of 24 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Held by 11 funds.
Estimated from the funds' index or underlying stock.
Futures (2026-11): 64,100
Basis +0.31% · implied rate +7.1%
Open interest 27,755 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
LigaChem Biosciences (리가켐바이오, KRX: 141080) is listed on KOSDAQ, in the Biotech & Pharma sector. Korean biopharmaceutical company focused on medicinal chemistry-based drug discovery, concentrating R&D on antibody-drug conjugates (ADCs), immuno-oncology, antibiotics and anti-fibrosis agents. Its shares closed at ₩63,900 on Oct 27, 2026, down 1.54% on the day, giving it a market value of ₩2.4T.
Korean biopharmaceutical company focused on medicinal chemistry-based drug discovery, concentrating R&D on antibody-drug conjugates (ADCs), immuno-oncology, antibiotics and anti-fibrosis agents. Its ConjuALL ADC platform technology (linkers, conjugation methods and payloads) is licensed to global and Chinese pharmaceutical companies, and it also develops synthetic small-molecule drugs. The company supplies medical devices and disposable medical consumables, such as implant surgical materials, to hospitals in the Seoul metropolitan area.
Written by AI from the company's latest annual report.
Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)
First patient dosing in Phase 1/2 trial already reported in recent days.
Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)
Same ADC first-dosing news as item 4; share move already reflected, lowered level.
Predicted impact: Low· Actual: +4.5% vs sector, volume 1.0× normal (5 trading days)
Same first global trial dosing news; repeat of item 4 with share reaction noted.
Titles in Korean until English translations are added.
Also known as: LigaChem Biosciences / 리가켐바이오 / 141080 / KRX:141080
Source: KRX statistical information